Hawkes David
BSc (Hons), PhD, Director, Molecular Biology and Biochemistry Victorian Cytology Service (VCS), Melbourne, Vic; Honorary Research Fellow, Department of Pharmacology and Therapeutics, University of Melbourne Vic.
Aust J Gen Pract. 2018 Jul;47(7):412-414. doi: 10.31128/AJGP-01-18-4471.
On 1 December 2017, Australia moved to a new National Cervical Screening Program (NCSP), which uses primary human papillomavirus (HPV) nucleic acid testing (NAT) followed by reflex liquid-based cytology for women aged between 25 and 74 years.
The aim of this article is to provide an overview of the different HPV NAT assays that satisfy the requirements for use in the renewed NCSP.
Australia has adopted innovative, evidence-based criteria for the inclusion of HPV NAT assays in the renewed NCSP. These include the requirements for detection of all 12 designated oncogenic HPV types, including separate detection and reporting of HPV 16 and 18; validation against reference assays showing sufficient sensitivity and specificity for the detection of underlying high-grade cervical disease; reproducibility; and the presence of cellularity and inhibition controls. Practitioners can feel assured that HPV NAT undertaken as part of the renewed NCSP will produce high‑quality results irrespective of location or pathology provider.
2017年12月1日，澳大利亚开始实施新的国家宫颈癌筛查计划（NCSP），该计划对25至74岁的女性采用人乳头瘤病毒（HPV）核酸检测（NAT）初筛，随后进行液基细胞学检查。
本文旨在概述满足新的NCSP使用要求的不同HPV NAT检测方法。
澳大利亚采用了创新的、基于证据的标准来将HPV NAT检测方法纳入新的NCSP。这些标准包括检测所有12种指定致癌HPV类型的要求，包括对HPV 16和18的单独检测和报告；与参考检测方法进行验证，以显示对潜在高级别宫颈疾病检测具有足够的敏感性和特异性；可重复性；以及存在细胞性和抑制对照。从业者可以放心，作为新的NCSP一部分进行的HPV NAT检测将产生高质量的结果，无论检测地点或病理提供者如何。
